

BC Cancer ST Program Updates for August 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites/ St. Paul's Hospital
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not** use the Copy Forward functionality to ensure that the updates apply.



- IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of premed, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: ULYOGGEMOX

Cycles/PowerPlans: ONCP LY ULYOGGEMOX Cycle 2 to 8 (Inpatient), ONCP LY ULYOGGEMOX Cycle 2 (Outpatient), ONCP LY ULYOGGEMOX Cycle 3 (Outpatient), ONCP LY ULYOGGEMOX Cycles 4 to 8 (Outpatient)

Changes:

- Created net new PowerPlan: ONCP LY ULYOGGEMOX (Inpatient) Cycle 2.
- Updated Regimen: ONC LY ULYOGGEMOX (Inpatient).

ONC LY ULYOGGEMOX (Inpatient) (Pending)

► Show additional details

Document Response View Responses

A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment

ONCP LY ULYOGGEMOX Pretreatment Plan

*Est. Start Date: 01-Aug-2026

Start Skip

Reminder for provider to order Cycle 1 Day 1, Day 8, and Day 15 PowerPlans at once

ONCP LY ULYOGGEMOX (Outpatient) Cycle 1 Days 1 and 2 - Cycle 1	*Est. Start Date: 01-Aug-2026
ONCP LY ULYOGGEMOX (Inpatient) Cycle 1 Day 8 - Cycle 1	*Est. Start Date: 08-Aug-2026
ONCP LY ULYOGGEMOX (Inpatient) Cycle 1 Day 15 - Cycle 1	*Est. Start Date: 15-Aug-2026
ONCP LY ULYOGGEMOX (Inpatient) Cycle 2 - Cycle 2	*Est. Start Date: 22-Aug-2026
ONCP LY ULYOGGEMOX (Inpatient) Cycles 3 to 8 - Cycle 3	*Est. Start Date: 12-Sep-2026

ONCP LY ULYOGGEMOX (Inpatient) Cycles 2 to 8

- Renamed to: ONCP LY ULYOGGEMOX Cycles 3 to 8.
- Removed 'Observe patient for 90 minutes post glofitamab infusion. May discontinue observation after 3 consecutive glofitamab doses with no CRS' from the glofitamab – oncology order comment.

☒ glofitamab (glofitamab - oncology)	30 mg, IV, once oncology, administer over: 4 hour, drug form: bag
	Day 1

ONCP LY ULYOGGEMOX (Outpatient) Cycle 2

- Added Day 2 treatment schedule.
- Glofitamab-oncology order updated to given on Day 1 only and 'Observe patient for 90 minutes post glofitamab infusion' removed from the order comment.
- Gemcitabine-oncology and oxaliplatin-oncology orders updated to be given on Day 2.
- Pre-medications for gemcitabine-oncology and oxaliplatin-oncology updated to Day 2.

- Added Zero Time order to Day 2.
- Updated Nurse/Chair Times.

For gemcitabine and oxaliplatin:		
☒ Ondansetron 8 mg, PO, once oncology, drug form: tab, Use Pa... Prior to gemcitabine. Day 2		-30 min Planned
If dexamethasone IV is being given for prior oxaliplatin hypersensitivity, deselect dexamethasone PO		
☒ Dexamethasone 8 mg, PO, once oncology, drug form: tab, Us... Prior to gemcitabine. Day 2		-30 min Planned
For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2):		
☐ Dexamethasone 20 mg, IV, once oncology, administer over: 15 m... 45 minutes prior to oxaliplatin. Day 2		-15 min
☐ Diphenhydramine 50 mg, IV, once oncology, administer over: 15 m... Y-site compatible with famotidine. 30 minutes p...		0 min
☐ Famotidine 20 mg, IV, once oncology, administer over: 15 m... Y-site compatible with diphenhydramine. 30 mi...		0 min

☒ Glofitamab (glofitamab - oncology) 30 mg, IV, once oncology, administer over: 4 ho... Day 1	0 min Planned	
☒ Gemcitabine (gemcitabine - oncology) 1,000 mg/m2, IV, once oncology, administer ove... Day 2		0 min Planned
Flush line with dextrose 5% pre and post oxaliplatin		
☒ Oxaliplatin (oxaliplatin - oncology) 100 mg/m2, IV, once oncology, administer over:.... Day 2		+30 min Planned

ONCP LY ULYOGGEMOX (Outpatient) Cycle 3 and ONCP LY ULYOGGEMOX (Outpatient) Cycles 4 to 8

- Removed 'Observe patient for 90 minutes post glofitamab infusion. May discontinue observation after 3 consecutive glofitamab doses with no CRS' from the glofitamab – oncology order comment.
- Updated Chair Times.

☒ Glofitamab (glofitamab - oncology)	30 mg, IV, once oncology, administer over: 2 hour, drug form: bag Day 1
--	--

Versioning: Yes

Jira: CST-374764

Net New Protocols

- ONC SA SAAVVPOIT
- ONCP SA SAAVVPOIT Pretreatment Plan
- ONCP SA SAAVVPOIT
- ONC SA SAAVVIT
- ONCP SA SAAVVIT Pretreatment Plan
- ONCP SA SAAVVIT

Jira: CST-373572, CST-373571

Jira Ticket #	CST-374764, CST-373572, CST-373571
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444